Взаимосвязь нарушений репродуктивной функции и высокого кардиоваскулярного риска

1. Vardas P., Maniadakis N., Bardinet I., Pinto F. The European Society of Cardiology Atlas of Cardiology: rationale, objectives, and methods. Eur. Heart J. 2016; 2(Suppl.1): 6-15. https://dx.doi.org/10.1093/ehjqcco/qcv020.
2. Kouvari M., Yannakoulia M., Souliotis K., Panagiotakos D.B. Challenges in sex- and gender- centered prevention and management of cardiovascular disease: implications of genetic, metabolic, and environmental paths. Angiology. 2018; 69 (Suppl.10): 843-53. https://dx.doi.org/10.1177/0003319718756732.
3. Halland F., Morken N.H., DeRoo L.A., Klungsоyr K., Wilcox A.J., Skjærven R. Association of women’s reproductive history with long-term mortality and effect of socioeconomic factors. Obstet. Gynecol. 2015; 126(Suppl. 6): 1181-7. https://dx.doi.org/10.1097/AOG.0000000000001155.
4. Verit F.F., Keskin S., Omer B., Yalcinkaya S., Sakar N. Is there any relationship between cardiovascular risk markers and young women with diminished ovarian reserve? Gynecol. Endocrinol. 2014; 30(10): 697-700. https://dx.doi.org/10.3109/09513590.2014.922948.
5. Parikh N.I., Jeppson R.P., Berger J.S., Eaton C.B., Kroenke C.H., LeBlanc E.S. et al. Reproductive risk factors and coronary heart disease in the women’s health initiative observational study. Circulation. 2016; 133(Suppl. 22):2149-58. https://dx.doi.org/10.1161/CIRCULATIONAHA.115.017854.
6. Verit F.F., Akyol H., Sakar M.N. Low antimullerian hormone levels may be associated with cardiovascular risk markers in women with diminished ovarian reserve. Gynecol. Endocrinol. 2016; 32(4): 302-5. https://dx.doi.org/10.3109/09513590.2015.1116065.
7. Senapati S. Infertility: a marker of future health risk in women? Fertil. Steril. 2018; 110(5): 783-9. https://dx.doi.org/10.1016/j.fertnstert.2018.08.058.
8. Адамян Л.В., Салимова Д.Ф., Кондратович Л.М. Патогенетические аспекты эндометриоз-ассоциированного бесплодия. Проблемы репродукции. 2015; 21(6): 90-6.
9. Parikh N.I., Cnattingius S., Mittleman M.A., Ludvigsson J.F., Ingelsson E. Subfertility and risk of later life maternal cardiovascular disease. Hum. Reprod. 2012; 27(2): 568-75. https://dx.doi.org/10.1093/humrep/der400.
10. Santoro L., D’Onofrio F., Campo S., Ferraro P.M., Tondi P., Campo V. et al. Endothelial dysfunction but not increased carotid intima-media thickness in young European women with endometriosis. Hum. Reprod. 2012; 27(5): 1320-6. https://dx.doi.org/10.1093/humrep/des062.
11. Santoro L., D’Onofrio F., Campo S., Ferraro P.M., Flex A., Angelini F. et al. Regression of endothelial dysfunction in patients with endometriosis after surgical treatment: a 2-year follow-up study. Hum. Reprod. 2014; 29(6):1205-10. https://dx.doi.org/10.1093/humrep/deu074.
12. Santoro L., D’Onofrio F., Flore R., Gasbarrini A., Santoliquido A. Endometriosis and atherosclerosis: what we already know and what we have yet to discover. Am. J Obstet. Gynecol. 2015; 213(3): 326-31. https://dx.doi.org/10.1080/07853890.2016.1252055.
13. Mu F., Rich-Edwards J., Rimm E.B., Spiegelman D., Missmer S.A. Endometriosis and risk of coronary heart disease. Circ. Cardiovasc. Qual. Outcomes. 2016; 9(3): 257-64. https://dx.doi.org/10.1186/s40738-017-0034-0.
14. Tripathy P., Sahu A., Sahu M., Nagy A. Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 217: 18-22. https://dx.doi.org/10.1016/j.ejogrb.2017.08.011.
15. Bajuk Studen K., Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr. Connect. 2018; 7(7): R238-51. https://dx.doi.org/10.1530/EC-18-0129.
16. Mahalingaiah S., Sun F., Cheng J.J., Chow E.T., Lunetta K.L., Murabito J.M. Cardiovascular risk factors among women with self-reported infertility. Fertil. Res. Pract. 2017; 3: 7. https://dx.doi.org/10.1186/s40738-017-0034-0.
17. Macut D., Antić I.B., Bjekić-Macut J. Cardiovascular risk factors and events in women with androgen excess. J. Endocrinol. Invest. 2015; 38(3): 295-301. https://dx.doi.org/10.1007 / s40618-014-0215-1.
18. Kurabayashi T., Mizunuma H., Kubota T., Hayashi K. Ovarian infertility is associated with cardiovascular disease risk factors in later life: A Japanese cross-sectional study. Maturitas. 2016; 83: 33-9. https://dx.doi.org/ 10.1016/j.maturitas.2015.08.015.
19. Papadakis G., Kandaraki E., Papalou O., Vryonidou A., Diamanti-Kandarakis E.Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol. 2017; 42(4): 340-55. https://dx.doi.org/10.23736/S0391-1977.17.02609-8.
20. Sales M.F., Sóter M.O., Candido A.L., Fernandes A.P., Oliveira F.R., Ferreira A.C. et al. Correlation between plasminogen activator inhibitor-1(PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome. Gynecol. Endocrinol. 2013; 29(10): 936-9. https://dx.doi.org/10.3109/09513590.2013.819086
21. Güldaş M., Altinkaya S.Ö., Nergiz S., Demircan-Sezer S., Yüksel H. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome. Gynecol. Endocrinol. 2015; 31(7): 536-9. https://dx.doi.org/10.3109/09513590.2015.1018161.
22. Victor V.M., Rovira-Llopis S., Bañuls C., Diaz-Morales N., Martinez de Marañon A., Rios-Navarro C. et al. A Insulin resistance in PCOS patients enhances oxidative stress and leukocyte adhesion: role of myeloperoxidase. PLoS One. 2016; 11(3): e0151960. https://dx.doi.org/10.1371/journal.pone.0151960.
23. Podfigurna-Stopa A., Czyzyk A., Grymowicz M., Smolarczyk R., Katulski K., Cajjowski K., Meczekalski B. Premature ovarian insufficiency: the context of long-term effects. J. Endocrinol. Invest. 2016; 39(9): 983-90. https://dx.doi.org/10.1007 / s40618-016-0467-z.
24. Wang H., Chen H., Qin Y., Shi Z., Zhao X., Xu J. et al. Risks associated with premature ovarian failure in Han Chinese women. Reprod. Biomed. Online. 2015; 30(4): 401-7. https://dx.doi.org/10.1016/j.rbmo.2014.12.013.
25. Daan N.M., Muka T., Koster M.P., Roeters van Lennep J.E., Lambalk C.B., Laven J.S. et al. Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age. J. Clin. Endocrinol. Metab. 2016; 101(9): 3306-15. https://dx.doi.org/10.1210/jc.2016-1141.
26. Podfigurna A., Męczekalski B. Cardiovascular health in patients with premature ovarian insufficiency. Management of long-term consequences. Prz. Menopauzalny. 2018; 17(3): 109-11. https://dx.doi.org/10.5114/pm.2018.78551.
27. Auriemma R.S., De Alcubierre D., Pirchio R., Pivonello R., Colao A. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev. Endocrinol. Metab. 2018; 13(2): 99-106. https://dx.doi.org/10.1080/17446651.2018.1434412.
28. Vilar L., Abucham J., Albuquerque J.L., Araujo L.A., Azevedo M.F., Boguszewski C.L. et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch. Endocrinol. Metab. 2018; 62(2): 236-63. https://dx.doi.org/10.20945/2359-3997000000032.
29. Haring R., Friedrich N., Völzke H., Vasan R.S., Felix SB., Dörr M. et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur. Heart J. 2014; 35(18): 1215-21. https://dx.doi.org/10.1093/eurheartj/ehs233.
30. Therkelsen K.E., Abraham T.M., Pedley A., Massaro J.M., Sutherland P., Hoffmann U., Fox C.S. Association between prolactin and incidence of cardiovascular risk factors in the Framingham Heart Study. J. Am. Heart Assoc. 2016; 5(2): e002640. https://dx.doi.org/10.1161/JAHA.115.002640.
31. Soto-Pedre E., Newey P.J., Bevan J.S., Leese G.P. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr. Connect. 2017; 6(8): 580-8. https://dx.doi.org/10.1530/EC-17-0171
32. Krogh J., Selmer C., Torp-Pedersen C., Gislason G.H., Kistorp C. Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm. Metab. Res. 2017; 49(6): 411-7. https://dx.doi.org/10.1055/s-0043-107243.
33. Zepiridis L.I., Grimbizis G.F., Tarlatzis B.C. Infertility and uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 34: 66-73. https://dx.doi.org/10.1016/j.bpobgyn.2015.12.001.
34. Haan Y.C., Diemer F.S., Van Der Woude L., Van Montfrans G.A., Oehlers G.P., Brewster L.M. The risk of hypertension and cardiovascular disease in women with uterine fibroids. J. Clin. Hypertens. (Greenwich). 2018; 20(4): 718-26. https://dx.doi.org/10.1111/jch.13253.
35. Uimari O., Auvinen J., Jokelainen J., Puukka K., Ruokonen A., Järvelin M.R. et al. Uterine fibroids and cardiovascular risk. Hum. Reprod. 2016; 31(12): 2689-703. https://dx.doi.org/10.1093/humrep/dew249.
36. Farland L.V., Grodstein F., Srouji S.S., Forman J.P., Rich-Edwards J., Chavarro J.E., Missmer S.A. Infertility, fertility treatment, and risk of hypertension. Fertil. Steril. 2015; 104(2): 391-7. https://dx.doi.org/10.1016/j.fertnstert.2015.04.043.
37. Westerlund E, Brandt L, Hovatta O, Wallen H, Ekbom A, Henriksson P. Incidence of hypertension, stroke, coronary heart disease, and diabetes in women who have delivered after in vitro fertilization: a population-based cohort study from Sweden. Fertil. Steril. 2014; 102(4): 1096-102. https://dx.doi.org/10.1016/j.fertnstert.2014.06.024.
38. Udell J.A., Lu H., Redelmeier D.A. Long-term cardiovascular risk in women prescribed fertility therapy. J. Am. Coll. Cardiol. 2013; 62(18): 1704-12. https://dx.doi.org/10.1016/j.jacc.2013.05.085.
39. Purewal S., Chapman S.C.E., van den Akker O.B.A. Depression and state anxiety scores during assisted reproductive treatment are associated with outcome: a meta-analysis. Reprod. Biomed. Online. 2018; 36(6): 646-57. https://dx.doi.org/10.1016/j.rbmo.2018.03.010.
40. Greil A.L., Shreffler K.M., Schmidt L., McQuillan J. Variation in distress among women with infertility: evidence from a population-based sample. Hum. Reprod. 2011; 26(8): 2101-12. https://dx.doi.org/10.1093/humrep/der148.
41. Fioranelli M., Bottaccioli A.G., Bottaccioli F., Bianchi M., Rovesti M., Roccia M.G.Stress and inflammation in coronary artery disease: a review psychoneuroendocrineimmunology-based. Front. Immunol. 2018; 9: 2031. https://dx.doi.org/10.3389/fimmu.2018.02031.
42. Hamer M., Kivimaki M., Stamatakis E., Batty G.D. Psychological distress as a risk factor for death from cerebrovascular disease. CMAJ. 2012; 184(13): 1461-6. https://dx.doi.org/10.1503/cmaj.111719
43. Lazzarino A.I., Hamer M., Stamatakis E., Steptoe A. Low socioeconomic status and psychological distress as synergistic predictors of mortality from stroke and coronary heart disease. Psychosom. Med. 2013; 75(3): 311-6. https://dx.doi.org/10.1097/PSY.0b013e3182898e6d.

Поступила 06.11.2018

Принята в печать 07.12.2018